chronic lymphocytic leukemia (cll) therapeutics

1. Chronic Lymphocytic Leukemia (CLL) Therapeutics - Pipeline Assessment and Market Forecasts to 2017

2. The CLL Therapeutics Market is Forecast to Show High Growth Until 2017 GlobalData estimates that the global CLL therapeutics market was valued at $475m in 2010, and is forecast to grow at a CAGR of 8% over the next seven years to reach $817m by 2017. This growth is primarily attributed to the increase in the treatment usage patterns, such as diseased population, treatment seeking population, diagnosis population, prescription population, and the launch of monoclonal antibodies in the recent past. Untapped Market Opportunity and Moderate Competition The CLL therapeutics market is relatively small compared to other cancers, yet untapped opportunity exists for companies with better disease cures and therapies with improved toxicities. The current competition in the global CLL therapeutics market is moderate, as the marketed products have been moderately successful in meeting demand. There are currently four key drugs (Campath, Treanda, Arzerra and Rituxan) which are moderately effective to meet the current unmet need. However there is a need for effective and more tolerable therapies. Therefore opportunity exists for new therapies to meet the unmet needs.

3. Monoclonal Antibodies Hold the Future for the CLL Market Monoclonal antibodies in the market and in clinical development will drive the future CLL therapeutics market. Monoclonal antibodies have been the mainstay of treatment and form the largest component of the market. Their use is expected to increase in the future and many new monoclonal antibodies are in clinical development, such as GA101, dacetuzumab, samalizumab, malituzumab and MOR208, which if approved could further increase their dominance in the market. Unmet Need Continues to Challenge Pipeline Drugs GlobalData’s research indicates that the CLL pipeline landscape is moderate with molecules in various phases of clinical development, defined as first-in-class, me-too and product extensions. The first-in-class molecules have distinct advantages over the currently used products in terms of better disease management. In early studies, these drugs also display improvements in safety, adverse events and efficacy profiles. They are expected to compete strongly with currently used drugs, offering equal or better efficacies and safety profiles, leading to increased patient and physician satisfaction. GlobalData, the industry analysis specialist, has released its new report, “Chronic Lymphocytic Leukemia (CLL) Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and

4. analysis on the global CLL therapeutics market. The report identifies the key trends shaping and driving the global CLL therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global CLL therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts. For further details, please click or add the below link to your browser: http://www.globaldata.com/reportstore/Report.aspx?ID=Chronic-Lymphocytic-Leukemia-%28CLL%29-Therapeutics-Pipeline-Assessment-and-Market-Forecasts-to-2017&ReportType=Industry_Report&coreindustry=Industry_Report&Title=Pharmaceuticals_and_Healthcare Visit our report store: http://www.globaldata.com

5. For more details contact: pressreleases@globaldata.com North America: +1 646 395 5477 Europe: +44 207 753 4299 +44 1204 543 533 Asia Pacific: +91 40 6616 6782